Skip to main content
. 2017 Nov 17;93(2):222–231. doi: 10.1002/ajh.24959

Figure 1.

Figure 1

Mean Quizartinib/AC886 Peak and Trough Plasma Concentrations. Mean quizartinib plasma peak concentrations increased 3‐fold to 4‐fold after 15 days of continued daily quizartinib administration at 40 mg/d [Panel A] and 60 mg/d [Panel B]. Mean AC886 plasma peak concentrations increased 5‐fold to 8‐fold after 15 days of continued daily quizartinib administration at 40 mg/d [Panel C] and 60 mg/d [Panel D]. Mean plasma trough concentrations of quizartinib [Panel E] and AC886 [Panel F] remained consistent from cycle 2 onward following continuous administration of quizartinib after allo‐HCT